Decoding RNA modifications
to revolutionize cancer and inflammation treatment
About Umlaut.bio
Umlaut.bio GmbH is a pioneering biotech company focused on developing first-in-biology therapeutic molecules to modify tRNA and target cancers and inflammatory diseases.
We target RNA sequences with specific modifications to influence the uncontrolled growth of cancer and autoimmune cells.
Our Mission
Umlaut.bio GmbH is a pioneering biotech company focused on developing first-in-biology therapies targeting cancer and inflammatory diseases. Small molecules will be developed inhibiting key steps in tRNA modification thereby preventing overactivation of a multitude of signalling molecules at scale. This is a hallmark of uncontrolled cancer growth as well as autoimmune diseases which can not be addressed with chemotherapy or targeting individual proteins.
Strategic Partners
Invested through Mission BioCapital Platinum Program 2023 and the Golden Ticket Program
Get in touch
Contact Us
We are happy to help you. Contact us by phone, email or using the contact form on our website.